Crescent Biopharma, Inc. (CBIO)

NASDAQ: CBIO · Real-Time Price · USD

16.84

+0.41 (2.50%)

Aug 7, 2026, 4:00 PM EDT - Market closed

Crescent Biopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 7, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	721	361	25	152	165	75
Market Cap Growth	235.17%	1323.71%	-83.31%	-7.77%	118.72%	-59.13%
Enterprise Value	550.61	153.55	32.08	110.92	117.81	-13.92
Last Close Price	16.84	11.86	24.90	236.00	303.00	144.00

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 7, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	60.66	33.30	-	15196.90	2196.86	64.95
PB Ratio	3.53	89.65	25363.20	-	-	-
P/TBV Ratio	102.05	30.66	16054.88	-	-	-

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 7, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	46.34	14.16	-	11091.80	1570.83	-12.00
EV/EBITDA Ratio	-	-	-	-	-	0.22
EV/EBIT Ratio	-	-	-	-	-	0.22
EV/FCF Ratio	-	-	-	-	-	0.24

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 7, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.01	0.01	-2.42	0	0	0
Net Debt / Equity Ratio	-42.24	-52.52	2716.00	-	-	-
Net Debt / EBITDA Ratio	1.01	1.39	-0.07	1.05	1.00	1.41
Net Debt / FCF Ratio	2.31	2.92	-0.43	1.18	1.01	1.55
Asset Turnover	-	0.08	0	0.00	0.00	0.01
Quick Ratio	9.26	6.41	3.62	6.11	5.39	7.63
Current Ratio	9.66	6.56	3.62	6.41	5.71	7.68
Return on Equity (ROE)	-92.19%	-167.78%	-330.33%	-90.78%	-75.05%	-60.49%
Return on Assets (ROA)	-79.65%	-110.64%	-98.94%	-80.87%	-64.87%	-53.50%
Return on Invested Capital (ROIC)	-4061.48%	-6247.73%	-2599.71%	-1834.55%	-1442.19%	-1266.82%
Return on Capital Employed (ROCE)	-91.45%	-132.59%	-124.18%	-96.49%	-75.57%	-59.60%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 7, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Buyback Yield / Dilution	-	-1515.09%	-1.79%	-20.58%	-2.10%	-12.54%
Total Shareholder Return	-	-1515.09%	-1.79%	-20.58%	-2.10%	-12.54%

SEC Filings: 10-K · 10-Q